|
Autistic Disorder
|
0.320 |
Biomarker
|
disease |
BEFREE |
Here we provide animal model evidence that supports this notion that CBP and its CH1 domain are relevant to autism.
|
26730956 |
2016 |
|
Autistic Disorder
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
In a boy with classic autism, the authors observed a de novo chromosome translocation between 4q and 5q and mapped the breakpoint site to within a proposed alternative transcript of EIF4E.
|
19556253 |
2009 |
|
Autistic Disorder
|
0.320 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells.
|
20388789 |
2010 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
|
17148679 |
2006 |
|
Lymphoma, Lymphocytic, Intermediate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
|
17148679 |
2006 |
|
Autism Spectrum Disorders
|
0.250 |
AlteredExpression
|
disease |
BEFREE |
Specifically, rpS6, p-eIF4E, TSC1 and p-MNK1 expression discriminated patients according to their clinical diagnosis, suggesting that components of protein synthesis signalling pathways might constitute a molecular signature of clinical severity in autism spectrum disorder.
|
30705255 |
2019 |
|
Autism Spectrum Disorders
|
0.250 |
Biomarker
|
disease |
BEFREE |
The cap-dependent translation initiation gene, EIF4E, is one of the most MIA-dysregulated of all ASD-associated genes and targeted network analyses demonstrate prominent MIA-induced transcriptional dysregulation of mTOR and EIF4E-dependent signaling.
|
28322282 |
2018 |
|
Autism Spectrum Disorders
|
0.250 |
Biomarker
|
disease |
BEFREE |
Although the key physiological functions affected by ASD-associated mutation of epigenetic regulators have been enigmatic, our findings are consistent with theoretical models involving CBP and p300 in ASD, and with a causative role for recently described ASD-associated CBP mutations.
|
26730956 |
2016 |
|
Autism Spectrum Disorders
|
0.250 |
AlteredExpression
|
disease |
BEFREE |
Previously, overexpression of the eukaryotic translation initiation factor 4E (eIF4E) led to ASD-like phenotype in mice.
|
25646590 |
2015 |
|
Autism Spectrum Disorders
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Based on these findings, we tested common EIF4E variants for association with overall ASD, with strict autism and with the strict high-functioning autism (strict HFA) subgroup, and their effect on repetitive and/or stereotypic behaviour.
|
24818597 |
2014 |
|
Autism Spectrum Disorders
|
0.250 |
Biomarker
|
disease |
MGD |
|
|
|
|
Multi-infarct dementia
|
0.200 |
Biomarker
|
disease |
RGD |
Effect of electroacupuncture on the expression of mTOR and eIF4E in hippocampus of rats with vascular dementia.
|
23053837 |
2013 |
|
Dementia, Vascular
|
0.200 |
Biomarker
|
disease |
RGD |
Electroacupuncture improves learning and memory ability by up-regulating expression of mTOR and eIF4E in the hippocampus of vascular dementia rats.
|
23053837 |
2013 |
|
Sepsis
|
0.200 |
Biomarker
|
disease |
RGD |
Acute oral leucine administration stimulates protein synthesis during chronic sepsis through enhanced association of eukaryotic initiation factor 4G with eukaryotic initiation factor 4E in rats.
|
17709445 |
2007 |
|
Myocardial Ischemia
|
0.200 |
Biomarker
|
disease |
RGD |
Inhibition of Cap-initiation complexes linked to a novel mechanism of eIF4G depletion in acute myocardial ischemia.
|
16439989 |
2006 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, garcinol treatment dose-dependently decreased the protein levels of p300/CBP (transcriptional cofactors and HATs) and p-Smad2/3 expression in the nucleus, thus impeding tumor cell proliferation and metastasis.
|
31371781 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, garcinol treatment dose-dependently decreased the protein levels of p300/CBP (transcriptional cofactors and HATs) and p-Smad2/3 expression in the nucleus, thus impeding tumor cell proliferation and metastasis.
|
31371781 |
2020 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eukaryotic initiation factor 4E(eIF4E), the mRNA cap-binding protein, has emerged as a key player to facilitate tumor progression through upregulated cap-dependent translation synchronized with enhanced cell division.
|
31782083 |
2020 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
This model provides a mechanistic framework for understanding how Cbp/p300 loss of function mutations impact on skin tumorigenesis and suggests potential therapeutic options in CBP/p300 mutated human cSCC.
|
31397888 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data demonstrate that Ajuba functions as a novel co-activator of ERα and that Ajuba/DBC1/CBP/p300 ternary complex may be a new target for developing therapeutics to treat breast cancer.
|
30597111 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that nAS-E inhibited breast cancer cell proliferation, migration, survival and suppressed osteoclast differentiation as well as bone resorption through inhibiting CREB-CBP interaction.
|
30461194 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that activation of the CXCR4-LASP1-eIF4F axis may contribute to the preferential translation of oncogenic mRNAs leading to breast cancer progression and metastasis.
|
31106142 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As eIF4E overexpression has been observed in a number of human diseases, most notably cancer, targeting this oncogenic translation initiation factor has emerged as a promising strategy for the development of novel anti-cancer therapeutics.
|
30735900 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Certain aspects of eIF4F regulation are consistent across cancer and neuroscience, whereas some results are more complicated to interpret, likely due to differences in the complexity of the brain, its billions of neurons and synapses, and its diverse cell types.
|
31416906 |
2019 |